About Omnicin:
Advancing New Solutions to Antibiotic Resistance
Omnicin Therapeutics is a privately owned Netherlands-based biotechnology company focused on developing innovative approaches to combat antimicrobial resistance.
Our lead development program, Bismocin™ (OTX003), combines the established clinical history of bismuth with proprietary, patent-pending technology designed to restore the effectiveness of existing antibiotics against resistant bacterial infections.
Omnicin is currently seeking a strategic buyer for either the Bismocin program, or the company as a whole. The opportunity includes a comprehensive development package supported by extensive preclinical research, intellectual property and regulatory documentation.
Company Information
Omnicin Therapeutics B.V.
MediTech Center
L.J. Zielstraweg 1
9713GW Groningen
The Netherlands
Business Focus: Development of novel approaches to antimicrobial resistance
Lead Asset: Bismocin™ (OTX003)
Transaction Opportunity: Company acquisition, asset acquisition or exclusive licensing
Interested in Bismocin?
We welcome enquiries from pharmaceutical companies, strategic investors and other qualified parties interested in acquiring or licensing the Bismocin program.